Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: mopgcw who wrote (1546)	3/16/2004 7:04:08 PM
From: mopgcw	Read Replies (1) \| Respond to of 1686

GS: Biogen Idec, Inc. EPS (FY Dec) 2004E $1.34, 2005E $1.70 Outperform/Neutral (BIIB) $52.91 CMS raised the Medicare payment on 9 drugs, including Avonex, given in physician offices. Effective 4/1/04, the rate would be 89%. Previously, the rate was cut from 95% in 2003 to 85% in 2004 as w/ most drugs in physician offices. The increase for Avonex is an exception to ensure adequate coverage of physician costs based on filings by BIIB which included actual data on sales prices. The increase is a slight positive as there was no increase for competing products, such as Rebif, Betaseron and Copaxone. There will be limited impact on earnings as Medicare patients represent less than 5% of the Avonex patients. We continue to rate BIIB Outperform based on earnings acceleration from potential launch of Antegren in '05 and data from 4 Phase III trials (combined potential of $2B in 04/05). Recent concerns about Avonex are probably overdone. BIIB shares are at 40X our '04 EPS or PEG of 1.8, in line with the group. The risks are slower sales, development failures, manufacturing, reimbursement & generics. Our coverage view is Neutral.